DBV TECHNOLOGIES |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.196 EUR | -0.33% |
|
-3.55% | -35.32% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -35.32% | 124M | C- | ||
| +4.41% | 69.91B | A | ||
| +10.97% | 9.03B | A- | ||
| -17.03% | 4.75B | A- | ||
| +37.51% | 4.31B | - | ||
| +3.92% | 3.88B | B- | ||
| +17.67% | 2.37B | B | ||
| -24.13% | 2.26B | C- | ||
| -29.70% | 2.2B | - | ||
| +9.09% | 1.98B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- DBV Stock
- Ratings DBV Technologies
